Form 8-K - Current report:
SEC Accession No. 0001999371-24-009889
Filing Date
2024-08-12
Accepted
2024-08-12 08:18:07
Documents
16
Period of Report
2024-08-12
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tonix-8k_081224.htm   iXBRL 8-K 30554
2 PRESS RELEASE OF THE COMPANY, AUGUST 12, 2024 ex99-01.htm EX-99.01 20389
3 RESULTS OF THE POSITIVE PHASE 3 RESILIENT TRIAL ex99-02.htm EX-99.02 14314
7 GRAPHIC ex99-02_001.jpg GRAPHIC 1851221
  Complete submission text file 0001999371-24-009889.txt   2803928

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20240812.xsd EX-101.SCH 3024
5 XBRL LABEL FILE tnxp-20240812_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tnxp-20240812_pre.xml EX-101.PRE 22365
18 EXTRACTED XBRL INSTANCE DOCUMENT tonix-8k_081224_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 241194958
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)